After Brexit, the UK runs its own cosmetic notification system under SCPN, requires a UK-based Responsible Person (RP), asks for an English Product Information File (PIF) kept for 10 years, and still treats Northern Ireland under EU rules. For a skincare brand planning UK market entry, these four pieces define the regulatory sequence before launch.
What Is the Difference Between UK and EU Cosmetic Regulation?
The core shift is that Great Britain (England, Scotland, Wales) no longer uses the EU’s CPNP portal. Instead, the Office for Product Safety and Standards (OPSS) manages the SCPN system. Northern Ireland, however, continues to follow EU rules including CPNP notification and an EU-based Responsible Person. This means a brand selling across the full UK and EU territory may need two notification tracks running in parallel.
Here is how the two systems compare side by side:
| Dimension | Great Britain (England, Scotland, Wales) | Northern Ireland / EU |
|---|---|---|
| Notification portal | SCPN (managed by OPSS) | CPNP (EU portal) |
| Responsible Person location | UK-based entity, physical address (no PO boxes or forwarding addresses) | EU or NI-based entity |
| PIF language | English, retained 10 years | Language of the EU member state where the RP is based |
| Adverse effect reporting | SUE reports to OPSS | SUE reports per EU framework |
The practical takeaway: a brand that already has EU compliance in place cannot simply extend it to Great Britain. The SCPN and the UK RP are separate requirements. Understanding EU market entry fundamentals helps frame the comparison, but the UK track stands on its own.
SCPN Notification: Who Reports, When, and What?
The SCPN submission is the UK equivalent of the CPNP notification. The Responsible Person submits product information through the SCPN portal before the product is placed on the Great Britain market. The notification covers product identity, category, Responsible Person details, formulation composition, and labeling information.
Timing matters. The notification should be completed before first placement on the market. If the formulation, product name, or RP details change afterward, the notification must be updated to remain accurate. Brands should treat SCPN as a living record rather than a one-time filing.
One additional obligation: Serious Undesirable Effects (SUE) must be reported to OPSS. Failure to report can result in fines. In England and Wales, the fine is unlimited; in Scotland, the reference cap is £5,000. These figures come from the statutory framework, but the exact penalty in any case depends on the circumstances and enforcement authority.
How to Set Up a UK Responsible Person — and What Address Traps Exist?
The Responsible Person must be a legal entity established in the UK with a physical address. This is where many non-UK brands run into problems. The system does not accept PO boxes, mail-forwarding services, or virtual office addresses that lack a real physical presence. The RP address must be a genuine UK location where the product information can be made available to enforcement authorities.
For brands outside the UK, the common route is to appoint a UK-based distributor, consultant, or regulatory agent as the Responsible Person through a written mandate. The mandate defines who holds the RP role, what responsibilities are delegated, and how product information is managed. Brands should confirm the RP arrangement before finalizing packaging artwork, because the RP name and address must appear on the label.
Since December 2022, labels for products placed on the GB market must bear the UK RP details. This deadline reflects the end of the transition period for existing products. For cosmetic labeling and claims, getting the RP information right on the artwork is a common compliance checkpoint.
English PIF and the 10-Year Retention Rule
The Product Information File must be compiled in English and retained for 10 years from the date the last batch of the product was placed on the market. The PIF typically includes the product description, formulation, safety assessment (CPSR), proof of effect or efficacy claims, GMP compliance statement, and — where applicable — animal testing status documentation.
The 10-year clock starts from the last placement on the market, not the first. If a product has been discontinued, the PIF must still be retained for the full statutory period. Brands should set up a document management process early, because the PIF is the primary dossier enforcement authorities request during inspections or post-market surveillance.
Northern Ireland’s Special Rules
Northern Ireland continues to follow EU cosmetic regulation. Products placed on the Northern Ireland market must go through CPNP, not SCPN, and the Responsible Person must be established in Northern Ireland or another EU member state. This dual-track situation exists because of the Windsor Framework arrangements.
For brands targeting only Great Britain, the SCPN route is sufficient. But if the commercial plan includes Northern Ireland or the Republic of Ireland, the EU compliance track must also be in place. Brands already familiar with EU cosmetic market entry will find the Northern Ireland track closely mirrors the EU system.
How to Schedule a Dual UK + EU Market Launch?
When the goal is to sell across both Great Britain and the EU, the sequencing should account for two notification systems, two Responsible Persons, and two label versions. The recommended approach is to map the dependencies early:
- Confirm the Responsible Persons — one UK-based RP for GB, one EU-based RP for EU and Northern Ireland. Both mandates should be signed before formulation finalization to avoid artwork delays.
- Prepare the PIF — the English PIF for GB and the EU-language PIF for the EU side. The safety assessment and formulation documentation can be shared, but the dossier formatting may differ.
- Submit notifications — SCPN for GB and CPNP for EU/NI. These can proceed in parallel once the RP and PIF are ready.
- Finalize labels — UK label with UK RP details, EU label with EU RP details. If selling to both markets, the artwork must accommodate both address blocks.
- Plan for nanomaterials — novel nanomaterials (those not used as colorants, preservatives, or UV filters) require a 6-month pre-notification. This timeline should be built into the launch schedule if the formulation includes such ingredients.
The nanomaterial notification window is one of the most commonly underestimated timelines. If the product uses a novel nanomaterial in a non-exempt function, the 6-month lead time effectively gates the launch date. For brands that also need EU fragrance allergen compliance, that deadline should be tracked in parallel.
Summary
UK market entry after Brexit means four things: a UK Responsible Person with a physical UK address, an SCPN notification before launch, an English PIF retained for 10 years, and awareness that Northern Ireland stays on EU rules. The SCPN and CPNP systems do not substitute for each other. Brands targeting both territories should plan dual tracks from the start, confirm RP mandates early, and build the nanomaterial notification window into the schedule if applicable. Regulatory specifics should always be confirmed against the current statute and consultant advice before artwork is finalized.
If your brand is planning UK or dual UK-EU entry, CHONGSHENG FUTURE (重生未来) can help align formulation, labeling, and regulatory documentation with your target market timeline. Share your product format, target markets, and launch schedule with our technical team, and we can assess the documentation route before sampling.